- Erasca Announces $45 Million Oversubscribed Private Placement Financing
- Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
- Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
- Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma
- Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway
- Erasca Reports Third Quarter 2023 Financial Results and Business Updates
- Erasca to Present at Upcoming Investor Conferences in November
- Erasca to Present at the Cantor Global Healthcare Conference
More ▼
Key statistics
On Friday, Erasca Inc (ERAS:NSQ) closed at 1.89, 25.17% above the 52 week low of 1.51 set on Dec 01, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.90 |
---|---|
High | 1.91 |
Low | 1.84 |
Bid | 1.86 |
Offer | 1.95 |
Previous close | 1.88 |
Average volume | 530.05k |
---|---|
Shares outstanding | 173.34m |
Free float | 138.09m |
P/E (TTM) | -- |
Market cap | 327.61m USD |
EPS (TTM) | -0.8327 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 21:00 BST.
More ▼